-
31دورية أكاديمية
المؤلفون: Huiyu Huang, Zhaojun Fu, Min Yang, Haigang Hu, Chao Wu, Lun Tan
مصطلحات موضوعية: Biophysics, Biochemistry, Medicine, Genetics, Molecular Biology, Immunology, Cancer, Biological Sciences not elsewhere classified, Mathematical Sciences not elsewhere classified, Mendelian randomization, Fracture risk, Circulating inflammatory protein, Ligament injury
الإتاحة: https://doi.org/10.6084/m9.figshare.25329742.v1Test
https://figshare.com/articles/journal_contribution/Additional_file_1_of_Levels_of_91_circulating_inflammatory_proteins_and_risk_of_lumbar_spine_and_pelvic_fractures_and_peripheral_ligament_injuries_a_two-sample_mendelian_randomization_study/25329742Test -
32دورية أكاديمية
المؤلفون: Zanardo M., Mennini C., Glielmo P., Fusco S., Albano D., Messina C.
المساهمون: M. Zanardo, C. Mennini, P. Glielmo, S. Fusco, D. Albano, C. Messina
مصطلحات موضوعية: Accuracy, FRAX®, Fracture risk, Radiographer, Training, Settore MED/36 - Diagnostica per Immagini e Radioterapia, Settore MED/50 - Scienze Tecniche Mediche Applicate
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38141277; info:eu-repo/semantics/altIdentifier/wos/WOS:001148510200001; volume:27; issue:1; firstpage:1; lastpage:8; numberofpages:8; journal:JOURNAL OF CLINICAL DENSITOMETRY; https://hdl.handle.net/2434/1026071Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85180584510
-
33دورية أكاديمية
المؤلفون: Fuggle, Nicholas R., Beaudart, Charlotte, Bruyere, Olivier, Abrahamsen, Bo, Al-Daghri, Nasser, Burlet, Nansa, Chandran, Manju, Rosa, Mario M., Cortet, Bernard, Demonceau, Celine, Dere, Willard, Halbout, Philippe, Hiligsmann, Mickael, Kanis, John A., Kaufman, Jean-Marc, Kurth, Andreas, Lamy, Olivier, Laslop, Andrea, Maggi, Stefania, Matijevic, Radmila, Mccloskey, Eugene, Mobasheri, Ali, Prieto Yerro, Maria C., Radermecker, Regis P., Sabico, Shaun, Al-Saleh, Yousef, Silverman, Stuart, Veronese, Nicola, Rizzoli, Rene, Cooper, Cyrus, Reginster, Jean-Yves, Harvey, Nicholas C.
المصدر: Fuggle , N R , Beaudart , C , Bruyere , O , Abrahamsen , B , Al-Daghri , N , Burlet , N , Chandran , M , Rosa , M M , Cortet , B , Demonceau , C , Dere , W , Halbout , P , Hiligsmann , M , Kanis , J A , Kaufman , J-M , Kurth , A , Lamy , O , Laslop , A , Maggi , S , Matijevic , R , Mccloskey , E , Mobasheri , A , Prieto Yerro , M C , Radermecker , ....
مصطلحات موضوعية: TRABECULAR BONE SCORE, FRACTURE RISK REDUCTION, COST-UTILITY ANALYSIS, HIP FRACTURE, OLDER MEN, POSTMENOPAUSAL WOMEN, PARATHYROID-HORMONE, ZOLEDRONIC ACID, MINERAL DENSITY, EUROPEAN-SOCIETY
العلاقة: https://cris.maastrichtuniversity.nl/en/publications/f5535f9d-ea87-49ab-a6e1-c6e55e747b3cTest
الإتاحة: https://doi.org/10.1038/s41584-024-01094-9Test
https://cris.maastrichtuniversity.nl/en/publications/f5535f9d-ea87-49ab-a6e1-c6e55e747b3cTest -
34دورية أكاديمية
المؤلفون: Rizzoli, René, Biver, Emmanuel
المصدر: ISSN: 1594-0667 ; Aging Clinical and Experimental Research, vol. 36, no. 1 (2024) 75.
مصطلحات موضوعية: info:eu-repo/classification/ddc/616, Bone mineral density, Cardiovascular risk, Diabetes, Fracture risk, Gut microbiota, Nutrition, Prebiotics, Probiotics, Humans, Diet, Mediterranean, Cultured Milk Products, Yogurt, Calcium, Dietary
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38502263; https://archive-ouverte.unige.ch/unige:176406Test; unige:176406
-
35دورية أكاديمية
المؤلفون: N. V. Toroptsova, E. L. Nasonov, Н. В. Торопцова, Е. Л. Насонов
المصدر: Rheumatology Science and Practice; Vol 62, No 2 (2024); 145-153 ; Научно-практическая ревматология; Vol 62, No 2 (2024); 145-153 ; 1995-4492 ; 1995-4484
مصطلحات موضوعية: клинические рекомендации, glucocorticoid-induced osteoporosis, fracture risk, osteoporosis treatment, guideline, глюкокортикоидный остеопороз, риск переломов, лечение остеопороза
وصف الملف: application/pdf
العلاقة: https://rsp.mediar-press.net/rsp/article/view/3543/2360Test; Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21(5):885-906. doi:10.1016/j.berh.2007.06.002; Баранова ИА, Ершова ОБ, Анаев ЭХ, Анохина ТН, Аношенкова ОН, Батын СЗ, и др. Оценка частоты и факторов риска низкоэнергетических переломов скелета по данным опроса больных хроническими воспалительными заболеваниями. Результаты многоцентрового исследования российской ассоциации по остеопорозу ГЛЮКОСТ. Остеопороз и остеопатии. 2014;17(3):9-14. doi:10.14341/osteo201439-14; Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: Relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383- 1389. doi:10.1093/rheumatology/39.12.1383; De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56(1):208-214. doi:10.1002/art.22294; Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporosis Int. 2011; 22:809-816. doi:10.1007/s00198-010-1524-7; Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2023;75(12):2405-2419. doi:10.1002/acr.25240; Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation’s direction and strength. J Clin Epidemiol. 2013;66(7):726-735. doi:10.1016/j.jclinepi.2013.02.003; Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.; GRADE Working Group. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926. doi:10.1136/bmj.39489.470347.AD; Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53-58. doi:10.1210/jc.2010-2704; Allen CS, Yeung JH, Vandermeer B, Homik J. Bisphosphonates for steroid-induced osteoporosis [review]. Cochrane Database Syst Rev. 2016;10:CD001347. doi:10.1002/14651858.CD001347.pub2; Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028-2039. doi:10.1056/NEJMoa071408; Chandran M. The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence. Arch Endocrinol Metab. 2022;66(5):724-738. doi:10.20945/2359-3997000000564; Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, et al.; HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373(9671):1253- 1263. doi:10.1016/S0140-6736(09)60250-6; Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, et al. Denosumab versus risedronate in glucocorticoidinduced osteoporosis: A multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018;6(6):445-454. doi:10.1016/S2213-8587(18)30075-5; Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346-3355. doi:10.1002/art.24879; Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology. 1999;60(2):68-73. doi:10.1002/(SICI)1096-9926(199908)60:23.0.CO;2-H; Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al.; Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945-1953. doi:10.1038/sj.ki.5000414; Hiramatsu R, Ubara Y, Sawa N, Sakai A. Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: A 2-year observational study. Nephrol Dial Transplant. 2021;36:1900-1907. doi:10.1093/ndt/gfaa359; Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, et al.; EUROFORS Investigators. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2008;93(3):852-860. doi:10.1210/jc.2007-0711; Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, et al. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res. 2013;28(6):1328-1336. doi:10.1002/jbmr.1853; Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004;19:745-751. doi:10.1359/JBMR.040117; Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial. Lancet. 2015;386(9999):1147-1155. doi:10.1016/S0140-6736(15)61120-5; Cosman F. Anabolic and antiresorptive therapy for osteoporosis: Combination and sequential approaches. Curr Osteoporos Rep. 2014;12:385-395. doi:10.1007/s11914-014-0237-9; Cosman F, Huang S, McDermott M, Cummings SR. Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses. J Bone Miner Res. 2022;37(11):2112-2120. doi:10.1002/jbmr.4705; Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. doi:10.1210/jc.2019-00221; Kendler D, Chines A, Clark P, Ebeling PR, McClung M, Rhee Y, et al. Bone mineral density after transitioning from denosumab to alendronate. J Clin Endocrinol Metab. 2020;105(3):e255-e264. doi:10.1210/clinem/dgz095; Tutaworn T, Nieves JW, Wang Z, Levin JE, Yoo JE, Lane JM. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: A retrospective study. Osteoporos Int. 2023;34(3):573-584. doi:10.1007/s00198-022-06648-9; Leder BZ, Tsai JN, Jiang LA, Lee H. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide follow-up study (DATA-Follow-up). Bone. 2017;98:54-58. doi:10.1016/j.bone.2017.03.006; Cosman F, Kendler DL, Langdahl BL, Leder BZ, Lewiecki EM, Miyauchi A, et al. Romosozumab and antiresorptive treatment: The importance of treatment sequence. Osteoporos Int. 2022;33(6):1243-1256. doi:10.1007/s00198-021-06174-0; Solling AS, Harslof T, Langdahl B. Treatment with zoledronate subsequent to denosumab in osteoporosis: A 2-year randomized study. J Bone Miner Res. 2021;36:1245-1254. doi:10.1002/jbmr.4305.; Napoli N, Langdahl BL, Ljunggren Ö, Lespessailles E, Kapetanos G, Kocjan T, et al. Effects of teriparatide in patients with osteoporosis in clinical practice: 42-month results during and after discontinuation of treatment from the European Extended Forsteo® Observational Study (ExFOS). Calcif Tissue Int. 2018;103(4):359-371. doi:10.1007/s00223-018-0437-x; Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, et al. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: A network meta-analysis. Osteoporos Int. 2016;27(6):1989-1998. doi:10.1007/s00198-015-3476-4; Kanis JA, McCloskey EV, Johansson H, Oden A, Strom O, Borgstrom F. Development and use of FRAX® in osteoporosis. Osteoporos Int. 2010;21(Suppl 2):407-413. doi:10.1007/s00198-010-1253-y; de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: A review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int. 2004;15(8):589-602. doi:10.1007/s00198-004-1614-5; Белая ЖЕ, Белова КЮ, Бирюкова ЕВ, Дедов ИИ, Дзеранова ЛК, Драпкина ОМ, и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Остеопороз и остеопатии. 2021;24(2):4-47. doi:10.14341/osteo12930; Лесняк ОМ (ред.). Остеопороз; 2-е издание, переработанное и дополненное. М.:ГЭОТАР-Медиа;2023.; https://rsp.mediar-press.net/rsp/article/view/3543Test
الإتاحة: https://doi.org/10.47360/1995-4484-2024-145-153Test
https://doi.org/10.1016/j.berh.2007.06.002Test
https://doi.org/10.14341/osteo201439-14Test
https://doi.org/10.1093/rheumatology/39.12.1383Test
https://doi.org/10.1002/art.22294Test
https://doi.org/10.1007/s00198-010-1524-7Test
https://doi.org/10.1002/acr.25240Test
https://doi.org/10.1016/j.jclinepi.2013.02.003Test
https://doi.org/10.1136/bmj.39489.470347.ADTest
https://doi.org/10.1210/jc.2010-2704Test -
36دورية أكاديمية
المؤلفون: Schini, M., Johansson, Helena, Harvey, Nicholas, Lorentzon, Karl Mattias, Kanis, John Anthony, McCloskey, Eugene
مصطلحات موضوعية: FRAX, Fractures, Calculator, Osteoporosis, Fracture risk, Epidemiology
وصف الملف: application/pdf
العلاقة: https://acuresearchbank.acu.edu.au/item/904q5/an-overview-of-the-use-of-theTest-fracture-risk-assessment-tool-frax-in-osteoporosis; https://acuresearchbank.acu.edu.au/download/3a0397d755b157a318faf256d2b30680b995905625b51ca430cba7356b0b25b0/868750/OA_Johansson_2023_An_overview_of_the_use_of.pdfTest; https://doi.org/10.1007/s40618-023-02219-9Test; Schini, M., Johansson, Helena, Harvey, Nicholas, Lorentzon, Karl Mattias, Kanis, John Anthony and McCloskey, Eugene. (2024). An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. Journal of Endocrinological Investigation. 47(3), pp. 501-511. https://doi.org/10.1007/s40618-023-02219-9Test
الإتاحة: https://doi.org/10.1007/s40618-023-02219-9Test
https://acuresearchbank.acu.edu.au/download/3a0397d755b157a318faf256d2b30680b995905625b51ca430cba7356b0b25b0/868750/OA_Johansson_2023_An_overview_of_the_use_of.pdfTest -
37دورية أكاديمية
المؤلفون: Damith Senanayake, Sachith Seneviratne, Mahdi Imani, Christel Harijanto, Myrla Sales, Peter Lee, Gustavo Duque, David C. Ackland
المصدر: JBMR Plus, Vol 7, Iss 12, Pp n/a-n/a (2023)
مصطلحات موضوعية: AGING, ANALYSIS/QUANTITATION OF BONE, BIOENGINEERING, DXA, FRACTURE RISK ASSESSMENT, ORTHOPAEDICS, Orthopedic surgery, RD701-811, Diseases of the musculoskeletal system, RC925-935
وصف الملف: electronic resource
العلاقة: https://doaj.org/toc/2473-4039Test
-
38دورية أكاديميةTraumatic rib fracture patterns associated with bone mineral density statuses derived from CT images
المؤلفون: Yilin Tang, Wei Hong, Xinxin Xu, Ming Li, Liang Jin
المصدر: Frontiers in Endocrinology, Vol 14 (2023)
مصطلحات موضوعية: artificial intelligence, bone mineral density, computed x-ray tomography, fracture risk assessment, rib fractures, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
وصف الملف: electronic resource
العلاقة: https://www.frontiersin.org/articles/10.3389/fendo.2023.1304219/fullTest; https://doaj.org/toc/1664-2392Test
-
39دورية أكاديمية
المؤلفون: Dimitri Martel, Anmol Monga, Gregory Chang
المصدر: Frontiers in Radiology, Vol 3 (2023)
مصطلحات موضوعية: osteoporotic fragility fractures, radiomic analysis, high resolution magnetic resonance imaging, fracture risk, textural feature, bone health assessment, Medical physics. Medical radiology. Nuclear medicine, R895-920
وصف الملف: electronic resource
العلاقة: https://www.frontiersin.org/articles/10.3389/fradi.2023.1293865/fullTest; https://doaj.org/toc/2673-8740Test
-
40دورية أكاديمية
المؤلفون: Huiran Jia, Wei Qu, Xiaoting Cai, Meiye Li, Ying Qian, Zhaoshun Jiang, Zongjing Zhang
المصدر: Frontiers in Endocrinology, Vol 14 (2023)
مصطلحات موضوعية: differentiated thyroid cancer, fracture risk assessment tool (FRAX), osteoporosis, TSH suppression therapy, bone mineral density (BMD), Diseases of the endocrine glands. Clinical endocrinology, RC648-665
وصف الملف: electronic resource
العلاقة: https://www.frontiersin.org/articles/10.3389/fendo.2023.1286947/fullTest; https://doaj.org/toc/1664-2392Test